vs
Side-by-side financial comparison of iSpecimen Inc. (ISPC) and Iterum Therapeutics plc (ITRM). Click either name above to swap in a different company.
iSpecimen Inc. is the larger business by last-quarter revenue ($713.1K vs $390.0K, roughly 1.8× Iterum Therapeutics plc). iSpecimen Inc. runs the higher net margin — -146.9% vs -2302.3%, a 2155.5% gap on every dollar of revenue.
Specimen Products is a Chicago-based manufacturer of custom guitars, tube amplifiers, and audio horn speakers led by luthier Ian Schneller. Specimen Products also offers courses in guitar and tube amplifier design, construction, and repair through their Chicago School of Guitar Making. The Specimen workshop offers repair services to the general public, making use of their collection of parts from rare and vintage manufacturers.
Iterum Therapeutics plc is a clinical-stage biopharmaceutical company specializing in developing innovative anti-infective therapies to treat infections caused by multi-drug resistant bacteria. Its lead product candidate targets indications including community-acquired bacterial pneumonia and complicated urinary tract infections, addressing unmet medical needs across global healthcare markets.
ISPC vs ITRM — Head-to-Head
Income Statement — Q2 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $713.1K | $390.0K |
| Net Profit | $-1.0M | $-9.0M |
| Gross Margin | 44.4% | — |
| Operating Margin | -255.4% | -1982.3% |
| Net Margin | -146.9% | -2302.3% |
| Revenue YoY | -75.1% | — |
| Net Profit YoY | 50.3% | -47.3% |
| EPS (diluted) | $-0.42 | $-0.20 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | — | $390.0K | ||
| Q2 25 | $713.1K | — | ||
| Q1 25 | $1.1M | — | ||
| Q4 24 | $1.5M | — | ||
| Q3 24 | $2.7M | — | ||
| Q2 24 | $2.9M | — | ||
| Q1 24 | $2.3M | — | ||
| Q4 23 | $2.6M | — |
| Q3 25 | — | $-9.0M | ||
| Q2 25 | $-1.0M | — | ||
| Q1 25 | $-1.7M | — | ||
| Q4 24 | $-6.0M | — | ||
| Q3 24 | $-1.4M | — | ||
| Q2 24 | $-2.1M | — | ||
| Q1 24 | $-2.9M | — | ||
| Q4 23 | $-3.1M | — |
| Q3 25 | — | — | ||
| Q2 25 | 44.4% | — | ||
| Q1 25 | 42.4% | — | ||
| Q4 24 | 13.5% | — | ||
| Q3 24 | 43.4% | — | ||
| Q2 24 | 51.9% | — | ||
| Q1 24 | 58.4% | — | ||
| Q4 23 | 44.6% | — |
| Q3 25 | — | -1982.3% | ||
| Q2 25 | -255.4% | — | ||
| Q1 25 | -154.9% | — | ||
| Q4 24 | -395.8% | — | ||
| Q3 24 | -64.1% | — | ||
| Q2 24 | -76.2% | — | ||
| Q1 24 | -131.0% | — | ||
| Q4 23 | -111.5% | — |
| Q3 25 | — | -2302.3% | ||
| Q2 25 | -146.9% | — | ||
| Q1 25 | -156.8% | — | ||
| Q4 24 | -409.8% | — | ||
| Q3 24 | -54.1% | — | ||
| Q2 24 | -73.6% | — | ||
| Q1 24 | -126.7% | — | ||
| Q4 23 | -119.3% | — |
| Q3 25 | — | $-0.20 | ||
| Q2 25 | $-0.42 | — | ||
| Q1 25 | $-0.71 | — | ||
| Q4 24 | $-5.40 | — | ||
| Q3 24 | $-2.10 | — | ||
| Q2 24 | $-3.72 | — | ||
| Q1 24 | $-6.36 | — | ||
| Q4 23 | $-19.23 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $11.0M |
| Total DebtLower is stronger | — | $20.0M |
| Stockholders' EquityBook value | $622.0K | $-7.4M |
| Total Assets | $6.0M | $32.5M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | $11.0M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $1.9M | — | ||
| Q3 24 | $1.8M | — | ||
| Q2 24 | $2.2M | — | ||
| Q1 24 | $2.1M | — | ||
| Q4 23 | $2.3M | — |
| Q3 25 | — | $20.0M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — |
| Q3 25 | — | $-7.4M | ||
| Q2 25 | $622.0K | — | ||
| Q1 25 | $1.7M | — | ||
| Q4 24 | $3.3M | — | ||
| Q3 24 | $4.7M | — | ||
| Q2 24 | $6.1M | — | ||
| Q1 24 | $6.8M | — | ||
| Q4 23 | $9.7M | — |
| Q3 25 | — | $32.5M | ||
| Q2 25 | $6.0M | — | ||
| Q1 25 | $6.8M | — | ||
| Q4 24 | $9.4M | — | ||
| Q3 24 | $11.3M | — | ||
| Q2 24 | $11.9M | — | ||
| Q1 24 | $12.5M | — | ||
| Q4 23 | $15.8M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-192.2K | $-7.4M |
| Free Cash FlowOCF − Capex | — | $-7.5M |
| FCF MarginFCF / Revenue | — | -1912.6% |
| Capex IntensityCapex / Revenue | — | 3.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | $-7.4M | ||
| Q2 25 | $-192.2K | — | ||
| Q1 25 | $-1.1M | — | ||
| Q4 24 | $-3.6M | — | ||
| Q3 24 | $-1.1M | — | ||
| Q2 24 | $-1.5M | — | ||
| Q1 24 | $-2.1M | — | ||
| Q4 23 | $345.1K | — |
| Q3 25 | — | $-7.5M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $-3.6M | — | ||
| Q3 24 | $-1.1M | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $-2.1M | — | ||
| Q4 23 | — | — |
| Q3 25 | — | -1912.6% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -242.7% | — | ||
| Q3 24 | -41.1% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -90.9% | — | ||
| Q4 23 | — | — |
| Q3 25 | — | 3.1% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.5% | — | ||
| Q3 24 | 0.5% | — | ||
| Q2 24 | 0.0% | — | ||
| Q1 24 | 0.4% | — | ||
| Q4 23 | 0.0% | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
